Systemic adverse effects and toxicities associated with immunotherapy: A review

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Mar 24, 2021; 12(3): 150-163
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.150

Table 2 Overview of some of the common immunotherapeutic agents and their proposed mechanisms

Agent	Mechanism of action
Ipilimumab	CTLA-4 inhibitor
Nivolumab	PD-1 inhibitor
Pembrolizumab	PD-1 inhibitor
Atezolizumab	PD-L1 inhibitor
Avelumab	PD-L1 inhibitor
Durvalumab	PD-L1 inhibitor
Talimogene Iaherparepvec	Cancer vaccine (directly destroys cancer cells, upregulates production of GM-CSF)
Necitumumab	EGFR inhibitor
Bevacizumab	VEGF inhibitor
Elotuzumab (anti-SLAMF7 monoclonal antibody)	Anti-SLAMF7 monoclonal antibody
Daratumumab (anti-CD38 monoclonal antibody)	Anti-CD38 monoclonal antibody
Lenalidomide	Immunomodulatory agent
Obinutuzumab	CD20 inhibitor
Ofatumumab	CD20 inhibitor
Blinatumomab	Bispecific T-cell engager
Trastuzumab	HER2/neu inhibitor
Dinutuximab	GD2-binding monoclonal antibody

CTLA-4: Cytotoxic T-lymphocyte associated protein 4; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1.

Citation: Kichloo A, Albosta M, Dahiya D, Guidi JC, Aljadah M, Singh J, Shaka H, Wani F, Kumar A, Lekkala M. Systemic adverse effects and toxicities associated with immunotherapy: A review. World J Clin Oncol 2021; 12(3): 150-163
URL: https://www.wjgnet.com/2218-4333/full/v12/i3/150.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i3.150

Kichloo A, Albosta M, Dahiya D, Guidi JC, Aljadah M, Singh J, Shaka H, Wani F, Kumar A, Lekkala M. Systemic adverse effects and toxicities associated with immunotherapy: A review. World J Clin Oncol 2021; 12(3): 150-163 [PMID: 33767971 DOI: 10.5306/wjco.v12.i3.150]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.